UroGen Pharma/$URGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About UroGen Pharma

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Ticker

$URGN
Primary listing

Industry

Biotechnology

Employees

234

UroGen Pharma Metrics

BasicAdvanced
$876M
-
-$3.04
0.67
-

What the Analysts think about UroGen Pharma

Analyst ratings (Buy, Hold, Sell) for UroGen Pharma stock.

Bulls say / Bears say

FDA approval of UroGen's bladder cancer drug, Zusduri, offers a non-surgical treatment option, potentially expanding the company's market share. (reuters.com)
Analysts maintain a 'buy' rating for UroGen Pharma, indicating confidence in the company's growth prospects. (etfdailynews.com)
UroGen's innovative gel-based chemotherapy formulation, designed to reduce tumor recurrence, positions the company as a leader in non-invasive cancer treatments. (reuters.com)
The FDA's Oncologic Drugs Advisory Committee voted against the risk/benefit profile of UroGen's UGN-102, leading to a significant stock price decline. (globenewswire.com)
UroGen reported a Q1 loss of $0.92 per share, missing analyst expectations and indicating financial challenges. (nasdaq.com)
A class action lawsuit has been filed against UroGen Pharma, alleging misleading disclosures about its clinical trials, which could lead to legal and financial repercussions. (globenewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

UroGen Pharma Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

UroGen Pharma Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $URGN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs